middle.news
Syntara’s SNT-5505 Shows Promising Interim Results in Tough Myelofibrosis Trial
11:02am on Friday 13th of June, 2025 AEST
•
Healthcare
Read Story
Syntara’s SNT-5505 Shows Promising Interim Results in Tough Myelofibrosis Trial
11:02am on Friday 13th of June, 2025 AEST
Key Points
73% of patients achieved significant symptom improvement (TSS50) at or beyond 24 weeks
44% of evaluable patients showed at least 25% spleen volume reduction (SVR25)
SNT-5505 targets lysyl oxidase activity to modify bone marrow fibrosis
No treatment-related serious adverse events reported; well tolerated alongside ruxolitinib
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE